Efficacy and safety of dulaglutide in the treatment of type 2 diabetes

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes - Efficacy and safety of dulaglutide in the treatment of type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027255

Enrollment

Registered

2017-05-06

Start date

2017-05-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus patients

Interventions

Dulaglutide 0.75mg/week, 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes whose HbA1c levels more than 7.0% (patients with advanced renal failure, GA levels more than 20%).

Exclusion criteria

Exclusion criteria: Patients with gastrointestinal bleeding, malignant tumor, liver cirrhosis, and thyroid function abnormalities.

Design outcomes

Primary

Measure	Time frame
Body composition (body fat percentage, fat mass, muscle mass, etc.) in the body composition analyzer (MLT - 50) on 3 months and 6 months after the administration of dulaglutide.	—

Secondary

Measure	Time frame
Changes of HbA1c, GA, body weight before and after the administration of dulaglutide.	—

Countries

Japan

Contacts

Public ContactTakahiro Yajima

Matsunami general hospital Department of Nephrology

yajima5639@gmail.com058-388-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026